MetaCap

Satellos Bioscience (MSLE) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 4.7% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -96.2% for OKUR. Satellos Bioscience is the larger company by market cap ($120.5 million vs $111.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MSLE-5.33%OKUR+4.65%
+124%+49%-25%
Nov 21, 20251 yearNov 20, 2026
MSLE-53.27%OKUR-96.62%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MSLE versus OKUR key metrics
MetricMSLEOKUR
Share price$5.68$2.70
Market cap$120.51M$111.21M
1-day change-2.07%-2.17%
YTD return-3.40%-6.90%
1-year return-5.33%+4.65%
5-year return-58.48%-96.16%
EPS (TTM)$-2.12$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-24.87M$-59.52M
52-week high$13.40$5.38
52-week low$5.44$2.01
Distance from 52-week high-57.60%-49.81%
Analyst consensusstrong_buynone
Avg. price target upside+325.53%+464.81%
Average volume51.19K335.78K
Shares outstanding21.22M40.50M
Employees1845
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Satellos Bioscience

MSLE stock →

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

MSLE vs OKUR FAQ

Which is bigger, Satellos Bioscience or OnKure Therapeutics?

Satellos Bioscience (MSLE) is larger, with a market capitalization of $120.51M compared with $111.21M for OnKure Therapeutics (OKUR).

Which stock has performed better over the past year, MSLE or OKUR?

OKUR returned +4.65% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.

Are Satellos Bioscience and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons